National Cancer Institute (NCI)s

National Cancer Institute (NCI)

444 Protocols (228 Active Accrual of new subjects, 216 Follow-up of previously enrolled subjects)

 002394-C:

Longitudinal Study of Individuals and Families with Aberrations in DDX41 or Similar Cancer Predisposition Variants

 002389-C:

A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2)

 002354-C:

Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors

 002268-C:

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

 002090-C:

ComboMATCH Treatment Trial N5: Randomized Trial of Neratinib, a Pan-ErbB Inhibitor alone or in combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and other Solid Tumors

 002088-C:

A Phase I Study of Autologous T Cells Transduced with Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, and other Hematologic Malignancies

 002060-C:

ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors

 002058-C:

A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-related Inhibitor M1774

 002041-C:

Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)

 002029-C:

A Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia

 002021-C:

Phase 1 Study with Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants with Mesothelin-Expressing Solid Tumors Including Mesothelioma

 001961-C:

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

 001951-C:

Natural History Study of Kaposi Sarcoma

 001924-C:

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

 001863-C:

Screening Protocol for Clinical Trial Eligibility

 001859-C:

A Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

 001844-C:

A Phase 1/2, Open-Label, Basket Study to Assess the Safety, Tolerability, and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors

 001842-C:

Phase I Trial of rhIL-15 plus Dinutuximab plus Irinotecan/Temozolomide for Children and Young Adults with Relapsed/Refractory Neuroblastoma

 001837-C:

A Phase I Study to Establish the Feasibility of Enolen(TM) for the Local Delivery of Enzalutamide in Patients with Prostate Cancer

 001827-C:

Phase 3, Multicenter, Randomized, Open-Label Study to Assess the Efficacy and Safety Of the Lifileucel (LN-144), Autologous Tumor-Infiltrating Lymphocytes [TIL]) Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Partici

 001811-C:

A Phase 1b/2 Study of Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma (RRMM)

 001796-C:

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

 001785-C:

Phase I Trial Integrating HLA-Haploidentical anti-CD19 CAR T cells with Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

 001778-C:

A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer

 001776-C:

A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

 001774-C:

A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T cells (CCR4 CAR T cells) for CCR4 expressing T-cell Malignancies including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

 001771-C:

EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMATCH Treatment Trial)

 001770-C:

Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers

 001756-C:

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

 001750-C:

A Prospective Study of MRI-Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

 001749-C:

ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors

 001733-C:

A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

 001732-C:

A Phase 1 Study of the Polymerase Theta (POL-Theta) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors

 001731-C:

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

 001730-C:

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination with Immunotherapy Vaccine PRGN-2009 in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

 001715-C:

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associ

 001713-C:

A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

 001711-C:

Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) with Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Parag

 001709-C:

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

 001696-C:

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

 001665-C:

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

 001662-C:

A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction with a Vaccine Directed Against these Antigens in Participants with Metastatic Cance

 001620-C:

Pilot Prospective Study for PET-CT Imaging in Participants with Relapsed/Refractory Acute Leukemias

 001615-C:

Phase 2 Trial of Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity in Neurofibromatosis Type 1

 001601-C:

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

 001600-C:

Phase 2 Study Evaluating the Functional Status of the Adrenal Glands with [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

 001599-C:

Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

 001587-C:

A Phase I Dose-escalation Study of Preoperative Radiation Therapy in Participants with Resectable Recurrent Abdominal Adrenocortical Carcinoma

 001572-C:

A Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)

 001570-C:

Phase I Dose Escalation Study of FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory Rhabdomyosarcoma

 001569-C:

A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

 001564-C:

A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 alone or in Combination with PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

 001563-C:

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

 001559-C:

A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

 001557-C:

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

 001556-C:

Phase II Trial of Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) without Testosterone Lowering Therapy

 001552-C:

Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors

 001548-C:

A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination with Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects with Biliary Tract Carcinoma (BTC)

 001547-C:

A First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

 001542-C:

Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants with Germline RUNX1 Deficiency

 001538-C:

A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

 001537-C:

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

 001535-C:

A Phase II Study of Sacituzumab Govitecan with or without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcin

 001534-C:

Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN Amplifications

 001525-C:

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

 001523-C:

A Phase II Study of Lurbinectedin with or without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

 001516-C:

Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer

 001109-C:

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

 001099-C:

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that

 001056-C:

Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

 000975-C:

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

 000958-C:

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

 000860-C:

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

 000792-C:

A Pilot Trial to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following CAR T-cell Induced Remission in Pediatric Patients with B Lineage Acute Lymphoblastic Leukemia

 000726-C:

A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

 000678-C:

Rare Tumors and Cancer Predisposition in Individuals and Families

 000666-C:

A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

 000661-C:

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

 000657-C:

Acceptance and Commitment Therapy for Caregivers of Children with a RASopathy: An Internal Pilot Feasibility Study and Follow-up Phase III Randomized Controlled Trial

 000643-C:

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

 000631-C:

Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell Therapy

 000628-C:

A Study of Prospective Monitoring of Subjects with Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL

 000613-C:

Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St

 000611-C:

A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer

 000509-C:

An Open Label, Multi-Center Roll-Over Study to Assess Long-Term Safety in Patients Who are Ongoing or Have Completed a Prior Global Novartis or GSK Sponsored Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Study and are Judged by the Investigator to B

 000491-C:

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

 000489-C:

Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies

 000481-C:

Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

 000478-C:

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Transplantation Followed by GVHD Prophylaxis with Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living with HIV (PLWH)

 000473-C:

A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma

 000404-C:

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

 000359-C:

Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies

 000354-C:

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

 000337-C:

Natural History Study of KSHV-Associated Multicentric Castleman's Disease

 000324-C:

Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

 000317-C:

A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma

 000307-C:

Phase II Study Evaluating the Efficacy of PDS01ADC in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

 000303-C:

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide Vs. Temozolomide and Olaparib For Advanced Pheochromocytoma And Paraganglioma

 000302-C:

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

 000277-C:

Imaging and Biopsy of People with HIV-1 Undergoing Analytic Treatment Interruption

Next 100 Protocols